Transmembrane activator and CAML interactor (TACI) : another potential target for immunotherapy of multiple myeloma?
Multiple myeloma (MM) has emerged as the next most likely oncological or hematological disease indication amenable for cellular immunotherapy. Much of the attention has been focused on B cell maturation antigen (BCMA) as a unique cell surface protein on myeloma cells that is available for monoclonal...
Saved in:
Main Authors: | Xu, Shengli, Lam, Kong-Peng |
---|---|
Other Authors: | School of Biological Sciences |
Format: | Article |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/145955 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Transmembrane activator and caml interactor (Taci): Another potential target for immunotherapy of multiple myeloma?
by: Xu, S., et al.
Published: (2021) -
Immunotherapy in Multiple Myeloma
by: Soekojo, Cinnie Yentia, et al.
Published: (2022) -
Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival
by: Reghunathan, R., et al.
Published: (2014) -
TACI constrains TH17 pathogenicity and protects against gut inflammation
by: Tan, Andy Hee-Meng, et al.
Published: (2020) -
SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma
by: Chong, Phyllis SY, et al.
Published: (2021)